![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/03\/WomeninBio_GinaFord-970.jpg\")
<\/p>\n <\/p>\n
BioNTX CEO Gina Ford [Photo: LinkedIn]<\/p>\n
BioNTX\u2019s board of directors has appointed Gina Ford, DPh., MBA, as the organization\u2019s chief executive officer.<\/p>\n
As CEO, Ford will lead BioNTX\u2019s strategic vision and operational priorities, drive disciplined growth, and ensure it provides meaningful, measurable value to its members, the nonprofit said. She will concentrate on boosting industry alignment, increasing the region\u2019s national visibility, and charting a clear roadmap to \u201cspeed innovation, attract investment, and improve long-term competitiveness in the life sciences sector across North Texas.\u201d<\/p>\n
\u201cIt\u2019s a privilege to step into the role of CEO and to work with the exceptional leaders, innovators, and partners who make North Texas a dynamic hub for bioscience,\u201d Ford said in a statement. \u201cBioNTX has built a powerful platform for connection and advancement, and I\u2019m committed to amplifying that impact as we enter this next stage of growth.\u201d<\/p>\n
\u201cI look forward to deepening strategic partnerships, broadening opportunities for innovation, and supporting the breakthroughs that will shape the region\u2019s future,\u201d Ford added<\/p>\n
Advancing biotech and improving patient outcomes<\/p>\n
Ford was chosen after a six-month review of multiple candidates led by \u201ca skilled executive recruiter\u201d and a committee of the BioNTX board, BioNTX said.<\/p>\n
\u201cThe search process was rigorous and comprehensive, ensuring we selected a leader with the vision and experience to guide BioNTX forward,\u201d said Kathleen Otto Rosenblum, former CEO of BioNTX. \u201cGina distinguished herself with her strong, future focused approach to advancing bioscience and healthcare innovation in North Texas. I\u2019m confident that under her leadership, BioNTX is well-positioned for the future.\u201d<\/p>\n
An accomplished leader with more than two decades of leadership experience across the life sciences, biotechnology, and pharmaceutical sectors, Ford has led organizations in corporate strategy, commercialization and globalization planning, and patient advocacy. She comes to BioNTX from Women In Bio, Inc.<\/a>, where she served as CEO and led exceptional growth in fundraising, engagement across national and local networks, and advanced programs supporting women in life science careers.<\/p>\n As a Doctor of Pharmacy with an MBA, Ford offers extensive experience spanning the bioscience life cycle, from startup and capital formation through commercialization and growth. Her long-standing commitment to improving patient outcomes is in excellent alignment with BioNTX\u2019s mission to \u201cadvance innovation that improves lives by putting the patient first,\u201d the organization said.<\/p>\n Leadership transition Kathleen Otto-Rosenblum, former CEO of BioNTX [Photo: BioNTX]<\/p>\n Ford\u2019s appointment follows Otto\u2019s retirement from BioNTX after a stellar career, most recently dedicated to advancing biotech innovation in North Texas. To support the leadership transition, Otto will stay involved and serve as an advisor to support Ford and BioNTX.<\/p>\n \u201cGina brings an exceptional depth of industry experience and an inspiring track record of growth, partnership-building, and strategic vision,\u201d said Jason Weitjes, BioNTX board chair. \u201cWe\u2019re confident that Gina\u2019s strategic acumen, industry relationships, and operational experience will build on BioNTX\u2019s strong foundation and support continued growth across our region. We are grateful for Kathleen\u2019s service and pleased that she will remain engaged with BioNTX as an advisor and member of our board.\u201d<\/p>\n Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n \u00a0<\/p>\n \tR E A D\u00a0\u00a0 N E X T\t<\/p>\n \t The Pittsburgh-headquartered nonprofit’s executive director, Dallas-based Gina Ford, takes up the newly created top post of the organization, which empowers women across biotech, pharma, and life sciences to lead, engage, and grow at every career stage.<\/p>\n \t Eido Bio\u2019s three co-founders are taking on menopause, research gaps, and a market where women\u2019s health \u201csort of starts and stops with birth control.\u201d The biotech startup is raising a Series A to launch clinical trials for a menopause treatment\u2014and help shift the science toward women.<\/p>\n \t Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress\u2014the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.<\/p>\n
\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/03\/BioNorthTexas-KathleenM.Otto_crop-970-1.jpg\")
<\/p>\n<\/a><\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/03\/EidoBio-founders-3up-970.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/photoillustration-GenrAb-CEO-Larry-Tiffany-whos-also-executive-chairman-and-director-of-Medcura-Phot.jpeg\")
<\/a><\/p>\n
![\"\"\/](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/03\/LightBio_FireflyPetunia2-970-970x464.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/03\/Signify_UTSW-2up-970.jpg\")
<\/a><\/p>\n